Perkins Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Perkins Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13,700	Closed	-$30K	–	100
2023 Q2	$30K	Sell	13,700 -32,000	-70%	-$66.4K	0.03%	92
2023 Q1	$116K	Hold	45,700	–	–	0.11%	85
2022 Q4	$85K	Sell	45,700 -4,000	-8%	-$9.97K	0.09%	84
2022 Q3	$128K	Hold	49,700	–	–	0.14%	85
2022 Q2	$96K	Hold	49,700	–	–	0.1%	91
2022 Q1	$148K	Sell	49,700 -10,500	-17%	-$39.5K	0.12%	90
2021 Q4	$270K	Sell	60,200 -16,000	-21%	-$75.9K	0.18%	85
2021 Q3	$370K	Hold	76,200	–	–	0.23%	80
2021 Q2	$520K	Buy	76,200 +350	+0.5%	+$2.83K	0.3%	72
2021 Q1	$536K	Buy	+75,850	New	+$546K	0.31%	71

Perkins Capital Management's PRTK Position: Q3 2023 in Review

Perkins Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 13,700 shares — an estimated $30K sold.

Perkins Capital Management first reported a position in PRTK in Q1 2021 and held it in 10 quarters. The position peaked at $536K in Q1 2021. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.

Perkins Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Perkins Capital Management sold 13,700 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $30K.
Perkins Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2021 and held it in 10 quarters.
Perkins Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $536K in Q1 2021.
0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.

Based on Perkins Capital Management's 13F filing for Q3 2023, filed 2 Nov 2023.